This is the text extract for June Tender Notification; Contact: Notifications, browse documents here.

---

30 June 2011

TENDER RESULTS

The PHARMAC Board (or Chief Executive under Delegated Authority) has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated 2 November 2010. As discussed in our 2010 tender consultation document, we are notifying tender decisions as they are made in 2011. This change is to provide maximum notification of upcoming changes to the market, specifically to incumbent suppliers. Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website – www.pharmac.govt.nz/schedule.asp. Where a product does not have a current pharmacode, suppliers are required to ensure a pharmacode has been received from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct pharmacode.

A430995 - qA18036

Page 1 of 6

---

2010/11 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2014 Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where no brand is listed.

Presentation; Pack size and type Tab 2.5 mg; 100 tablets, bottle Subsidy and price $2.45 Sole supply brand (Supplier) Apo-Amlodipine (Amlodipine) Date of listing 1 January 2012 Sole Subsidised Supply date 1 April 2012

Chemical name Amlodipine

2.

Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows: Chemical name Presentation; Pack size and type Tab 5 mg; 100 tablets, bottle Tab 10 mg; 100 tablets, bottle Tab long-acting 150 mg; 60 tablets, bottle Tab long-acting 800 mg; 30 tablets, blister Inj 50 mg per ml, 2 ml; 5 ampoules Tab 10 mg; 100 tablets, bottle Tab 15 mg; 100 tablets, bottle Current subsidy and price $7.33 $11.79 $11.52 $9.12 $20.95 $1.98 ($5.89) $2.45 ($8.13) New subsidy and price $2.65 $4.15 $11.52 $8.12 $19.90 $5.89 $8.13 Sole supply brand (Supplier) Apo-Amlodipine (Amlodipine) Apo-Amlodipine (Amlodipine) Pytazen SR (Douglas) Brufen SR (Abbott) Ferrum H (Aspen) Ox-Pam (Douglas) Ox-Pam (Douglas) Date of subsidy change Sole Subsidised Supply date

Amlodipine Amlodipine Dipyridamole Ibuprofen Iron polymaltose Oxazepam* Oxazepam*

1 August 2011 1 August 2011 1 August 2011 1 August 2011 1 August 2011 1 August 2011

1 November 2011 1 November 2011 1 November 2011 1 November 2011 1 November 2011 1 November 2011 1 November 2011

* Oxazepam 10 mg and 15 mg tablets will be fully sudsidised from 1 August 2011.

A430995 - qA18036

Page 2 of 6

---

3.

Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows: Chemical Name Presentation; Pack size and type Current subsidy and price New subsidy and price Sole supply brand (Supplier) Date of listing/subsidy change for tender winning brand 1 December 2011 Date of reference pricing of other listed brands Sole Subsidised Brand (Supplier) Supply date (and affected by delisting of other reference pricing listed brands) and delisting 1 May 2012 Ethics Ibuprofen (Multichem) Brufen*

Ibuprofen

Tab 200 mg; 1,000 tablets, blister

$16.00

$12.75

Arrowcare (Arrow)

1 February 2012

* The subsidy for ibuprofen 400 mg and 600 mg tablets (Brufen) will be reduced due to the reduction in price of the reference product (ibuprofen 200 mg tablets). The new subsidies will be $0.77 per 30 tablets for the 400 mg tablets and $1.15 per 30 tablets for the 600 mg tablets. The 400 mg and 600 mg tablets are not being delisted.

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

4. Tenders awarded to pharmaceuticals where no brand is listed.

Presentation; Pack size and type Tab 2.5 mg; 100 tablets, bottle Hospital Supply Brand (Supplier) Apo-Amlodipine (Amlodipine) DV Limit 1%

The decisions were as follows:

Chemical Name Amlodipine

Pack price $2.45

Listing date 1 January 2012

Hospital Supply Status date 1 March 2012

5.

Tenders awarded to listed pharmaceuticals where only the current brand is listed.

Presentation; Pack size and type Tab 5 mg; 100 tablets, bottle Tab 10 mg; 100 tablets, bottle Current pack price $7.33 $11.79 New pack price $2.65 $4.15 Hospital Supply Brand (Supplier) Apo-Amlodipine (Amlodipine) Apo-Amlodipine (Amlodipine) DV Limit 1% 1% Date of price change 1 August 2011 1 August 2011 Hospital Supply Status date 1 October 2011 1 October 2011

The decisions were as follows:

Chemical Name Amlodipine Amlodipine

A430995 - qA18036

Page 3 of 6

---

Chemical Name

Presentation; Pack size and type Inj 500 mg; 1 vial Tab long-acting 150 mg; 60 tablets, bottle Tab long-acting 800 mg; 30 tablets, blister Inj 50 mg per ml, 2 ml; 5 ampoules

Current pack price $1.69

New pack price $1.90

Hospital Supply Brand (Supplier) Cefotaxime Sandoz (Sandoz) Pytazen SR (Douglas) Brufen SR (Abbott) Ferrum H (Aspen)

DV Limit 1%

Date of price change

Hospital Supply Status date

Cefotaxime

1 August 2011

1 October 2011

Dipyridamole Ibuprofen Iron polymaltose

$11.52 $9.12 $20.95

$11.52 $8.12 $19.90

1% 1% 1%

1 August 2011 1 August 2011

1 October 2011 1 October 2011 1 October 2011

6.

Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

Presentation; Pack size and type Inj 1 g; 10 vials Current pack price $1.90 (per 1 injection) New pack price $15.58 (per 10 injections) Hospital Supply Brand (Supplier) DBL Cefotaxime (Hospira) DV Limit Date of listing/price change for tender winning brand 1 September 2011 Hospital Supply Status date (and delisting of other listed brands) 1 November 2011 Brand (Supplier) to be delisted Cefotaxime Sandoz (Sandoz)

The decisions were as follows:

Chemical Name

Cefotaxime

1%

A430995 - qA18036

Page 4 of 6

---

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

The PHARMAC Board (or Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2010/11 Invitation to Tender, dated 2 November 2010:

Chemical Name Bupivacaine Hydrochloride with Adrenaline Bupivacaine Hydrochloride with Adrenaline Bupivacaine Hydrochloride with Adrenaline Bupivacaine Hydrochloride with Adrenaline Bupivacaine Hydrochloride with Adrenaline Bupivacaine Hydrochloride with Adrenaline Dacarbazine Dacarbazine Dacarbazine Dacarbazine Daunorubicin Dobutamine Emtricitabine Ephidrine Fusidic acid Glipizide Heparinised saline Hypromellose Ibuprofen * Line Item Inj 0.25% with 1:400,000 of adrenaline, 10 ml Inj 0.25% with 1:400,000 of adrenaline, 10 ml theatre pack Inj 0.25% with 1:400,000 of adrenaline, 20 ml Inj 0.5% with 1:200,000 of adrenaline, 10 ml Inj 0.5% with 1:200,000 of adrenaline, 10 ml theatre pack Inj 0.5% with 1:200,000 of adrenaline, 20 ml Inj 100 mg Inj 1000 mg Inj 500 mg Inj 600 mg Inj 20 mg Inj 250 mg Cap 200 mg Inj 3 mg per ml, 10 ml prefilled syringe Eye drops 1% Tab 5 mg Inj 100 iu per ml, 5 ml prefilled syringe Eye drops 0.5% with or without dextran Tab 200 mg Chemical Name Ibuprofen Intra-Uterine Device Lignocaine (lidocaine) Lithium Carbonate Octreotide (somatostatin analogue) Octreotide (somatostatin analogue) Octreotide (somatostatin analogue) Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Oxycodone Oxycodone Pethidine Hydrochloride Pravastatin Tenoxicam Line Item Tab 400 mg IUD Topical soln 4% Tab long-acting 400 mg LAR inj 10 mg LAR inj 20 mg LAR inj 30 mg 1 mg per ml, 10 ml pre-filled syringe 1 mg per ml, 50 ml prefilled syringe Cap 10 mg Cap 20 mg Cap 5 mg Oral liq 5 mg per 5 ml Inj 10 mg per ml, 1 ml Inj 10 mg per ml, 2 ml Inj 50 mg per ml Inj 50 mg per ml, 1.5 ml Tab 10 mg Inj 20 mg

*Only the hospital tender for ibuprofen tab 200 mg has been declined.

A430995 - qA18036

Page 5 of 6

---

The PHARMAC Board (or Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2009/10 Invitation to Tender, dated 4 December 2009:

Chemical Name Dexamethasone Dexamethasone Dexamethasone Fluorouracil sodium Miconazole Line Item Tab 0.5 mg Tab 1 mg Tab 4 mg Inj 25 mg per ml, 100 ml Oral gel 20 mg per g Chemical Name Phenobarbitone Tobramycin Topotecan Topotecan Line Item Inj 200 mg per ml, 1 ml Powder BP Inj 1 mg Inj 4 mg

The PHARMAC Board (or Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2008/09 Invitation to Tender, dated 23 December 2008:

Chemical Name Felodipine Line Item Tab 2.5 mg Chemical Name Line Item

For products included in the 2009/10 Invitation to Tender and 2010/11 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or Chief Executive) approval. We will keep you informed of any updates regarding such tender products as decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.

A430995 - qA18036

Page 6 of 6